This trial is testing a new drug for men with prostate cancer that has spread and is resistant to hormone therapy.
- Prostate Cancer
8 Primary · 20 Secondary · Reporting Duration: Up to approximately 4 years
1 Treatment Group
Administration of CC-94676
1 of 1
122 Total Participants · 1 Treatment Group
Primary Treatment: CC-94676 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · Male Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent has recruitment for this clinical experiment been successful?
"This medical trial necessitates 122 participants that meet the qualifications. Potential volunteers can join from Sibley Memorial Hospital in Washington, D.C., and UAB in Birmingham, Alabama." - Anonymous Online Contributor
Is CC-94676 a reliable option for patient treatment?
"The safety of CC-94676 is rated as 1 due to its current Phase 1 status; this signifies that only limited data exists for both efficacy and safety." - Anonymous Online Contributor
Is the enrollment period for this trial still open?
"The clinicaltrials.gov database confirms that this medical trial is recruiting patients at present, with the original post dated June 22nd 2020 and the last editing occuring on December 1st 2022." - Anonymous Online Contributor
How widespread are the implementations of this experiment in Canada?
"Sibley Memorial Hospital in Washington D.C., UAB in Birmingham, Alabama and Florida Cancer Specialists in Sarasota, FL are all hosting participating sites for this medical trial alongside 23 other clinical locations." - Anonymous Online Contributor